Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Time to Sell?
by Jessica Moore · The Cerbat GemAstellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $14.21, but opened at $13.51. Astellas Pharma shares last traded at $13.40, with a volume of 3,399 shares trading hands.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on ALPMY shares. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday. Finally, Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Astellas Pharma currently has an average rating of “Hold”.
View Our Latest Analysis on ALPMY
Astellas Pharma Stock Performance
The company’s 50 day moving average price is $15.35 and its 200-day moving average price is $14.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. The company has a market cap of $24.23 billion, a PE ratio of 12.47 and a beta of 0.08.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.28 billion. Equities research analysts anticipate that Astellas Pharma Inc. will post 1.29 earnings per share for the current fiscal year.
About Astellas Pharma
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).